Evaluation of allogeneic cell transplantation in acute myeloid leukemia I (ETAL I)
Zusammenfassung der Projektergebnisse
In summary, the results of this prospective randomized trial, the first of its kind, suggest that allogeneic HCT performed immediately after achievement of a first CR in patients with cytogenetically defined intermediate-risk AML ≤ 60 years of age and an available sibling or unrelated donor does not seem to convey a survival advantage. Despite an increased incidence of relapse after conventional consolidation chemotherapy, salvage allogeneic HCT can be regarded as an effective treatment option. The early identification and allocation of a suitable donor during induction therapy seems to be warranted in intermediate-risk patients being eligible transplant candidates. However, allogeneic HCT in CR1 significantly reduced the relapse risk and is was not associated with relevant impairments in quality of life. With the advent of personalized strategies for monitoring of residual disease, delayed allogeneic transplantation can be regarded as a valid treatment algorithm in intermediate-risk AML with an available donor.
Projektbezogene Publikationen (Auswahl)
- Study Alliance Leukemia (SAL). Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations. Ann Oncol. 2017 Nov 1;28(11):2793-2798
Heidrich K, Thiede C, Schäfer-Eckart K, Schmitz N, Aulitzky WE, Krämer A, Rösler W, Hänel M, Einsele H, Baldus CD, Trappe RU, Stölzel F, Middeke JM, Röllig C, Taube F, Kramer M, Serve H, Berdel WE, Ehninger G, Bornhäuser M, Schetelig J
(Siehe online unter https://doi.org/10.1093/annonc/mdx500) - Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. Lancet Haematol. 2018 Apr;5(4):e161-e169
Fasslrinner F, Schetelig J, Burchert A, Kramer M, Trenschel R, Hegenbart U, Stadler M, Schäfer-Eckart K, Bätzel M, Eich H, Stuschke M, Engenhart-Cabillic R, Krause M, Dreger P, Neubauer A, Ehninger G, Beelen D, Berdel WE, Siepmann T, Stelljes M, Bornhäuser M
(Siehe online unter https://doi.org/10.1016/s2352-3026(18)30022-x) - Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol. 2018 Dec;19(12):1668-1679
Platzbecker U, Middeke JM, Sockel K, Herbst R, Wolf D, Baldus CD, Oelschlägel U, Mütherig A, Fransecky L, Noppeney R, Bug G, Götze KS, Krämer A, Bochtler T, Stelljes M, Groth C, Schubert A, Mende M, Stölzel F, Borkmann C, Kubasch AS, von Bonin M, Serve H, Hänel M, Dührsen U, Schetelig J, Röllig C, Kramer M, Ehninger G, Bornhäuser M, Thiede C
(Siehe online unter https://doi.org/10.1016/s1470-2045(18)30580-1) - Validation of the Revised Pretransplant Assessment of Mortality Score in Patients with Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 Sep;24(9):1947-1951
Middeke JM, Kollinger F, Baldauf H, Stölzel F, Wermke M, von Bonin M, Sockel K, Link CS, Teipel R, Röllig C, Thiede C, Platzbecker U, Ehninger G, Bornhäuser M, Schetelig J
(Siehe online unter https://doi.org/10.1016/j.bbmt.2018.05.021) - Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019 Apr;25(4):e128-e140
Zeiser R, Beelen DW, Bethge W, Bornhäuser M, Bug G, Burchert A, Christopeit M, Duyster J, Finke J, Gerbitz A, Klusmann JH, Kobbe G, Lübbert M, Müller-Tidow C, Platzbecker U, Rösler W, Sauer M, Schmid C, Schroeder T, Stelljes M, Kröger N, Müller LP
(Siehe online unter https://doi.org/10.1016/j.bbmt.2019.01.016) - Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. Nat Commun. 2019 Mar 25;10(1):1065
Noviello M, Manfredi F, Ruggiero E, Perini T, Oliveira G, Cortesi F, De Simone P, Toffalori C, Gambacorta V, Greco R, Peccatori J, Casucci M, Casorati G, Dellabona P, Onozawa M, Teshima T, Griffioen M, Halkes CJM, Falkenburg JHF, Stölzel F, Altmann H, Bornhäuser M, Waterhouse M, Zeiser R, Finke J, Cieri N, Bondanza A, Vago L, Ciceri F, Bonini C
(Siehe online unter https://doi.org/10.1038/s41467-019-08871-1)
